


A few quick answers from me below:



Subject: questions on vaccination

## Dear Colleagues,

Because our next meeting is a couple of weeks out, I hope it is OK to share with you (confidentially, given how sensitive this topic is) five questions that we are urgently trying to get some insights on, in the context of **analysing strategies to speed up vaccination** (just one example that is being considered: halving doses). This topic is probably being considered also in some of your countries, hence an exchange would seem valuable.

Should any of you have any input on these topics, we would really appreciate it!

Hopefully we can get out of this vaccination bottleneck asap.

All the best and have a good weekend!

5.1.2e

## Questions:

- 1. Is there any information on protection from symptomatic SARS-CoV-2 infection between 1 and 3 months after first vaccination with RNA vaccines without a second dose vaccination in this time period? My office can send you the links to papers from the UK experience (England and Scotland). You may also want to look at the FDA papers for Moderna which show interesting data on a good effects from single dose.
- 2. Is there any estimate if and to which extent SARS-CoV-2 specific memory B and T cells decay between 1 and 3 months after single-dose vaccination? No I don't think there are robust data on this yet
- 3. Is there any indication for severe secondary infection with the new viral variants in convalescents of SARS-CoV-2 infection? Probably worth looking at the Siren study (we will send)
- 4. Is there any data that second dose deferral of the RNA vaccines leads to a better protection after second dose, as suggested for the AstraZeneca vaccine? No not yet.
- 5. Is there any protection data for half-dose vaccination? Not that I am aware of, but AZ did have some data with reduced dose that is published.